NOTCH1 and acute lymphoblastic leukemia: These NOTCH1Mutated LIC were uniquely susceptible to targeted inhibition with a therapeutic human NOTCH1 monoclonal antibody selective for the NRR (hN1 mAb), while normal hematopoietic progenitors were spared thereby highlighting the cell type and context specific effects of NOTCH signaling [13], and the importance of oncogenic addiction to NOTCH1 signaling in T-ALL LIC maintenance.